Nicolas Lechevalier

9PUBLICATIONS
26CO-AUTHORS
Immunogenetics (incl. genetic immunology)Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Medical mycologyRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|May 31, 2024
Imatinib with intensive chemotherapy in AML with t(9;22)(q34.1;q11.2)/BCR::ABL1. A DATAML registry study.

Camille Gondran, Pierre-Yves Dumas, Emilie Bérard

|Feb 24, 2024
Dismal outcome of refractory or relapsing patients with myelodysplasia-related acute myeloid leukemia partially alleviated by intensive chemotherapy.

Harmony Leroy, Noémie Gadaud, Emilie Bérard

|Nov 22, 2022
The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance.

Victor-Emmanuel Brett, Nicolas Lechevalier, Franck Trimoreau

|Nov 01, 2022
Prognostic Impact of Unsupervised Early Assessment of Bulk and Leukemic Stem Cell Measurable Residual Disease in Acute Myeloid Leukemia.

Alban Canali, Inès Vergnolle, Sarah Bertoli

|Aug 16, 2022
Phenotypically-defined stages of leukemia arrest predict main driver mutations subgroups, and outcome in acute myeloid leukemia.

François Vergez, Laetitia Largeaud, Sarah Bertoli

|Nov 14, 2021
Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes.

Jean Galtier, Camille Alric, Emilie Bérard

Pageof 2

Frequent Collaborators

6 joint publications

Christian Récher

5 joint publications

François Vergez

5 joint publications

Jean-Philippe Vial

5 joint publications

Sarah Bertoli